深入研究肿瘤血管异质性分子对于肿瘤诊断、血管靶向治疗等具有重要意义。
And it is significant for the diagnosis of tumors and the therapy targeting tumor vasculatures to research the heterogeneous molecules further.
本发明所要解决的技术问题是提供一种转染效率高且具有肿瘤血管靶向性的阳离子脂质体。
The invention aims at solving the technical problem of proving a cationic liposome with high transfection efficiency and tumor vascular targeting.
这些多肽序列在肿瘤血管靶向治疗，肿瘤血管特异性分子标志物试剂的研制方面将具有巨大的潜在价值。
These polypeptide sequences have great potential in the targeting treatment of tumor veins and the development of the symbol reagent of the specific molecule of the tumor veins.
以引起血管形成的蛋白作为靶向，肿瘤的生长可以停止下来。
By targeting the proteins that lead to angiogenesis, tumor growth can be halted.
利用靶向性血栓药物实现对实体瘤血管的选择性栓塞是一种新颖的抗肿瘤策略。
It is a promising anti-tumor strategy to selectively induce thrombosis in tumor vessels by using targeted vascular embolization drug.
同时采用超声辐射力法以增加靶向性微泡造影剂在血管壁上的黏附效率，改善成像的性能。
Meanwhile, the ultrasonic radiation force method is used to get the higher adhering efficiency for the targeted micro-bubble contrast agent, which will improve the imaging quality.
目的利用包裹阿霉素的血管内皮生长因子（VEGF）脂质体于体外靶向杀伤肿瘤血管内皮细胞。
ObjectiveTo evaluate the targeting ability and cytotoxicity of adriamycin liposomes conjugated with VEGF in vitro.
随着分子生物学研究的进展，表皮生长因子受体抑制剂、血管内皮生长因子抑制剂等分子靶向药物的研究成为热点之一。
With the advancement of the study of molecular biology, the research of the molecular targeted drugs such as EGFR inhibitor and VEGF inhibitor, become one of the hot spots.
使用特定药理学制剂如抗氧化剂和PKC抑制剂，靶向血管内皮生长因子表达可能证明对治疗糖尿病性视网膜病变是有效的。
Targeting VEGF expression with specific pharmacological agents, such as antioxidants and PKC inhibitors, may prove efficacious for the treatment of diabetic retinopathy.
使用特定药理学制剂如抗氧化剂和PKC抑制剂，靶向血管内皮生长因子表达可能证明对治疗糖尿病性视网膜病变是有效的。
Targeting VEGF expression with specific pharmacological agents, such as antioxidants and PKC inhibitors, may prove efficacious for the treatment of diabetic retinopathy.
应用推荐